Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu1132
425P Real-world treatment patterns and outcomes in patients with advanced gastric cancer in Japan1002
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)941
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers763
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing syste739
114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging536
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings508
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)494
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia463
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy454
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)445
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada435
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort416
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin414
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study392
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals346
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling332
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer331
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study330
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma321
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway316
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study314
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor302
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country274
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era255
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)252
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience245
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction234
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer232
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported 223
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India217
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma217
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre214
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care209
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report200
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC191
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes189
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis187
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE183
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%181
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China180
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia177
Imatinib’s last lessons? A roadmap to cure174
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies165
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform165
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia165
256P Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer164
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma164
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study163
235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE162
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers158
978P Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective, 158
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial153
1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis153
1748P A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)152
907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carci147
727P Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China146
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age141
138P Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics141
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals139
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma137
1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study136
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with adva131
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies127
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)125
SY19-5 Utility of circulating tumor DNA-based MRD monitoring following allogeneic transplantation in adult acute lymphoblastic leukemia119
MO29-5 Correlation of COVID-19 pandemic and medical seeking behaviour in breast cancer patients at Siloam Hospitals Lippo Village115
MO43-6 UPRISE study: anxiety in patients with urothelial cancer in postoperative period -relation to patient demographics-115
MO47-4 Neutrophil-lymphocyte ratio predicts prognosis in bone metastasis: meta-analysis of retrospective studies113
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review111
MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials111
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer110
P28-3 Clinical application of portable fNIRS to measure cognitive impairment after chemotherapy in a colorectal cancer patient110
P11-9 Association of Charlson Comorbidity Index and safety of endoscopic resection gastric cancer patients: systematic review107
P38-2 Efficacy and safety of lazertinib in the treatment of EGFR-mutated non-small cell lung cancer: a systematic review106
SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective105
283P Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study104
LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial102
618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer100
821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma100
418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer99
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)96
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES94
1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)92
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 s91
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial91
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up90
60P A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report90
787P First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors90
0.19824600219727